Anthony Price - Bio Path Accounting Finance
| BPTHDelisted Stock | USD 0.19 0.01 5.00% |
Executive
Anthony Price is Accounting Finance of Bio Path Holdings
| Phone | 832 742 1357 |
| Web | https://www.biopathholdings.com |
Bio Path Management Efficiency
The company has return on total asset (ROA) of (1.9409) % which means that it has lost $1.9409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5974) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities.Bio Path Holdings currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Bio Path Holdings has a current ratio of 15.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Bio Path until it has trouble settling it off, either with new capital or with free cash flow. So, Bio Path's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio Path Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio Path's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Satyajit Mitra | Akari Therapeutics PLC | 50 | |
| Jaime Xinos | Achieve Life Sciences | N/A | |
| Sophie Mukadam | Benitec Biopharma Ltd | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 69 | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Kevin Shaw | NextCure | 50 | |
| Minghao Sun | Capricor Therapeutics | N/A | |
| Deborah Ascheim | Capricor Therapeutics | 59 | |
| Sebastien Maloveste | NextCure | N/A | |
| Bryan Dulhunty | Benitec Biopharma Ltd | N/A | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| Steven CPA | NextCure | 62 | |
| David JD | Pulmatrix | 66 | |
| Alan MD | Crinetics Pharmaceuticals | 62 | |
| Michael Graham | Benitec Biopharma Ltd | N/A | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Mark CPA | Achieve Life Sciences | 56 | |
| Udayan MD | NextCure | N/A | |
| MD III | Akari Therapeutics PLC | 71 | |
Management Performance
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 |
Bio Path Holdings Leadership Team
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan MacKenzie, Consultant | ||
| Thomas Walker, Consultant | ||
| MBA Ashizawa, Development Research | ||
| Michael MBA, VP Operations | ||
| Peter MBA, Chairman, CoFounder | ||
| Jeffery MD, Consultant | ||
| Victoria Rac, Regulatory Consultant | ||
| Anthony Price, Accounting Finance | ||
| Douglas Morris, Co-Founder and Director | ||
| MBA MBA, Development Research | ||
| Anthony MBA, Accounting Finance |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bio Path a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.6 | ||||
| Return On Asset | -1.94 | ||||
| Current Valuation | 531.06 K | ||||
| Shares Outstanding | 5.77 M | ||||
| Shares Owned By Institutions | 7.41 % | ||||
| Number Of Shares Shorted | 79.35 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Bio OTC Stock
If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |